Journal of Pathology and Translational Medicine

Original Article

Mesothelin Expression in Gastric Adenocarcinoma and Its Relation to Clinical Outcomes: Song-Hee Han, Mee Joo, Hanseong Kim, Sunhee Chang; J Pathol Transl Med. 2017;51(2):122-128. Published online February 15, 2017; DOI: https://doi.org/10.4132/jptm.2016.11.18

7,064 View
162 Download
17 Web of Science
15 Crossref

Background
Although surgical resection with chemotherapy is considered effective for patients with advanced gastric cancer, it remains the third leading cause of cancer-related death in South Korea. Several studies have reported that mesothelial markers including mesothelin, calretinin, and Wilms tumor protein 1 (WT1) were positive in variable carcinomas, associated with prognosis, and were evaluated as potential markers for targeted therapy. The aim of this study was to assess the immunohistochemical expression of mesothelial markers (mesothelin, calretinin, and WT1) in gastric adenocarcinoma and their relations to clinocopathological features and prognosis. Methods: We evaluated calretinin, WT1, and mesothelin expression by immunohistochemical staining in 117 gastric adenocarcinomas. Results: Mesothelin was positively stained in 30 cases (25.6%). Mesothelin expression was related to increased depth of invasion (p = .002), lymph node metastasis (p = .013), and presence of lymphovascular (p = .015) and perineural invasion (p = .004). Patients with mesothelin expression had significantly worse disease-free survival rate compared with that of nonmesothelin expression group (p = .024). Univariate analysis showed that mesothelin expression is related to short-term survival. None of the 117 gastric adenocarcinomas stained for calretinin or WT1. Conclusions: Mesothelin expression was associated with poor prognosis. Our results suggest that mesothelin-targeted therapy should be considered as an important therapeutic alternative for gastric adenocarcinoma patients with mesothelin expression.

Citations

Citations to this article as recorded by

Targeting Mesothelin in Solid Tumours: Anti-mesothelin Antibody and Drug Conjugates
Quincy Chu
Current Oncology Reports.2023; 25(4): 309. CrossRef
High expression of mesothelin in plasma and tissue is associated with poor prognosis and promotes invasion and metastasis in gastric cancer
Suryendu Saha, Chitranjan Mukherjee, Dipjit Basak, Prasun Panja, Pronoy Kanti Mondal, Ranajoy Ghosh, Aniket Halder, Abhijit Chowdhury, Gopal Krishna Dhali, Bitan Kumar Chattopadhyay, Saurabh Ghosh, Somsubhra Nath, Shalini Datta
Advances in Cancer Biology - Metastasis.2023; 7: 100098. CrossRef
Novel Anti-Mesothelin Nanobodies and Recombinant Immunotoxins with Pseudomonas Exotoxin Catalytic Domain for Cancer Therapeutics
Minh Quan Nguyen, Do Hyung Kim, Hye Ji Shim, Huynh Kim Khanh Ta, Thi Luong Vu, Thi Kieu Oanh Nguyen, Jung Chae Lim, Han Choe
Molecules and Cells.2023; 46(12): 764. CrossRef
Immunotherapy for lung cancer: Focusing on chimeric antigen receptor (CAR)-T cell therapy
Tongqing Xue, Xiang Zhao, Kun Zhao, Yan Lu, Juan Yao, Xianguo Ji
Current Problems in Cancer.2022; 46(1): 100791. CrossRef
Cellular immunotherapy in gastric cancer: adoptive cell therapy and dendritic cell-based vaccination
Elnaz Faghfuri, Mahdi Abdoli Shadbad, Amir Hossein Faghfouri, Narges Soozangar
Immunotherapy.2022; 14(6): 475. CrossRef
Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors
Sören Weidemann, Pauline Gagelmann, Natalia Gorbokon, Maximilian Lennartz, Anne Menz, Andreas M. Luebke, Martina Kluth, Claudia Hube-Magg, Niclas C. Blessin, Christoph Fraune, Katharina Möller, Christian Bernreuther, Patrick Lebok, Till S. Clauditz, Frank
Biomedicines.2021; 9(4): 397. CrossRef
Host Mesothelin Expression Increases Ovarian Cancer Metastasis in the Peritoneal Microenvironment
Tyvette S. Hilliard, Brooke Kowalski, Kyle Iwamoto, Elizabeth A. Agadi, Yueying Liu, Jing Yang, Marwa Asem, Yuliya Klymenko, Jeff Johnson, Zonggao Shi, Gifty Marfowaa, Madeleine G. Yemc, Phillip Petrasko, M. Sharon Stack
International Journal of Molecular Sciences.2021; 22(22): 12443. CrossRef
CAR-T Cell Therapy—An Overview of Targets in Gastric Cancer
Dominika Bębnowska, Ewelina Grywalska, Paulina Niedźwiedzka-Rystwej, Barbara Sosnowska-Pasiarska, Jolanta Smok-Kalwat, Marcin Pasiarski, Stanisław Góźdź, Jacek Roliński, Wojciech Polkowski
Journal of Clinical Medicine.2020; 9(6): 1894. CrossRef
Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors
Brendan L. Hagerty, Guillaume J. Pegna, Jian Xu, Chin-Hsien Tai, Christine Alewine
Biomolecules.2020; 10(7): 973. CrossRef
Phase I/II clinical trial of a Wilms’ tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer
Wen Zhang, Xu Lu, Peilin Cui, Chunmei Piao, Man Xiao, Xuesong Liu, Yue Wang, Xuan Wu, Jingwei Liu, Lin Yang
Cancer Immunology, Immunotherapy.2019; 68(1): 121. CrossRef
Mesothelin as a target for cervical cancer therapy
Korinna Jöhrens, Lea Lazzerini, Jana Barinoff, Jalid Sehouli, Guenter Cichon
Archives of Gynecology and Obstetrics.2019; 299(1): 211. CrossRef
A targeted proteomics approach reveals a serum protein signature as diagnostic biomarker for resectable gastric cancer
Qiujin Shen, Karol Polom, Coralie Williams, Felipe Marques Souza de Oliveira, Mariana Guergova-Kuras, Frederique Lisacek, Niclas G. Karlsson, Franco Roviello, Masood Kamali-Moghaddam
EBioMedicine.2019; 44: 322. CrossRef
Mesothelin as a biomarker for targeted therapy
Jiang Lv, Peng Li
Biomarker Research.2019;[Epub] CrossRef
Antibody drug conjugates under investigation in phase I and phase II clinical trials for gastrointestinal cancer
Alexis D. Leal, Anuradha Krishnamurthy, Lia Head, Wells A. Messersmith
Expert Opinion on Investigational Drugs.2018; 27(11): 901. CrossRef
Mesothelin‑targeted second generation CAR‑T cells inhibit growth of mesothelin‑expressing tumors in�vivo
Lin Ye, Yuqing Lou, Liming Lu, Xiaohong Fan
Experimental and Therapeutic Medicine.2018;[Epub] CrossRef

First
Prev
Page of 1
Next
Last

Search